Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue

Heterozygous germline mutations in the gene encoding the bone morphogenetic protein type II receptor cause familial pulmonary arterial hypertension (PAH). We previously demonstrated that the substitution of cysteine residues in the ligand-binding domain of this receptor prevents receptor trafficking...

Full description

Saved in:
Bibliographic Details
Published in:Human molecular genetics 2008-10, Vol.17 (20), p.3180-3190
Main Authors: Sobolewski, Anastasia, Rudarakanchana, Nung, Upton, Paul D., Yang, Jun, Crilley, Trina K., Trembath, Richard C., Morrell, Nicholas W.
Format: Article
Language:English
Subjects:
Amino Acid Substitution
Biological and medical sciences
Biological Transport, Active - drug effects
Bone Morphogenetic Protein Receptors, Type I - metabolism
Bone Morphogenetic Protein Receptors, Type II - genetics
Bone Morphogenetic Protein Receptors, Type II - metabolism
Cell Membrane - metabolism
Cell receptors
Cell structures and functions
Endoplasmic Reticulum - drug effects
Endoplasmic Reticulum - metabolism
Fundamental and applied biological sciences. Psychology
Genetics of eukaryotes. Biological and molecular evolution
Germ-Line Mutation
Glycerol - pharmacology
HeLa Cells
Humans
Hypertension, Pulmonary - drug therapy
Hypertension, Pulmonary - genetics
Hypertension, Pulmonary - metabolism
Medical sciences
Miscellaneous
Models, Biological
Molecular and cellular biology
Phenylbutyrates - pharmacology
Pneumology
Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases
Recombinant Proteins - genetics
Recombinant Proteins - metabolism
Signal Transduction
Smad Proteins, Receptor-Regulated - metabolism
Thapsigargin - pharmacology
Transfection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Heterozygous germline mutations in the gene encoding the bone morphogenetic protein type II receptor cause familial pulmonary arterial hypertension (PAH). We previously demonstrated that the substitution of cysteine residues in the ligand-binding domain of this receptor prevents receptor trafficking to the cell membrane. Here we demonstrate the potential for chemical chaperones to rescue cell-surface expression of mutant BMPR-II and restore function. HeLa cells were transiently transfected with BMPR-II wild type or mutant (C118W) receptor constructs. Immunolocalization studies confirmed the retention of the cysteine mutant receptor mainly in the endoplasmic reticulum. Co-immunoprecipitation studies of Myc-tagged BMPR-II confirmed that the cysteine-substituted ligand-binding domain mutation, C118W, is able to associate with BMP type I receptors. Furthermore, following treatment with a panel of chemical chaperones (thapsigargin, glycerol or sodium 4-phenylbutyrate), we demonstrated a marked increase in cell-surface expression of mutant C118W BMPR-II by FACS analysis and confocal microscopy. These agents also enhanced the trafficking of wild-type BMPR-II, though to a lesser extent. Increased cell-surface expression of mutant C118W BMPR-II was associated with enhanced Smad1/5 phosphorylation in response to BMPs. These findings demonstrate the potential for rescue of mutant BMPR-II function from the endoplasmic reticulum. For the C118W mutation in the ligand-binding domain of BMPR-II, cell-surface rescue leads to at least partial restoration of BMP signalling. We conclude that enhancement of cell-surface trafficking of mutant and wild-type BMPR-II may have therapeutic potential in familial PAH.
ISSN:0964-6906
1460-2083
DOI:10.1093/hmg/ddn214